BETADERM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BETADERM (BETADERM).
Betamethasone dipropionate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins (lipocortins) and inhibition of arachidonic acid release, thereby reducing prostaglandin and leukotriene synthesis.
| Metabolism | Betamethasone dipropionate is metabolized primarily in the liver via ester hydrolysis to betamethasone, which is further metabolized via CYP3A4-mediated hydroxylation and reduction. The metabolites are excreted in urine and bile. |
| Excretion | Renal excretion of metabolites (mainly as glucuronide and sulfate conjugates) accounts for approximately 60-70% of elimination; fecal/biliary excretion accounts for 30-40%. |
| Half-life | Terminal elimination half-life is approximately 18-36 hours (mean ~24 hours) following topical application; systemic half-life after oral administration is similar, reflecting prolonged tissue retention. |
| Protein binding | Approximately 85-90% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Apparent volume of distribution (Vd) is approximately 1.4-3.0 L/kg, indicating extensive tissue distribution, particularly into skin and adipose tissue. |
| Bioavailability | Topical: 1-5% systemic bioavailability from intact skin; increased to 10-30% with damaged skin (e.g., psoriasis, eczema). No oral formulation available; intralesional injection: ~100% systemic bioavailability from the injection site. |
| Onset of Action | Topical: noticeable improvement in inflammation and pruritus within 1-2 hours; peak effect by 6-12 hours. Intralesional: onset within a few hours to 1 day. |
| Duration of Action | Topical: duration of effect lasts 12-24 hours after a single application; with chronic use, duration may extend due to drug accumulation in skin. Intralesional: effects may persist for weeks to months. |
| Molecular Weight | 392.47 Da (betamethasone dipropionate) |
Topical: Apply a thin film to affected skin twice daily; maximum 100 g per week for adults.
| Dosage form | CREAM |
| Renal impairment | No adjustment required for topical use; systemic absorption is minimal. |
| Liver impairment | No adjustment required for topical use; systemic absorption is minimal. |
| Pediatric use | Apply a thin film to affected skin twice daily; use caution to avoid prolonged use and systemic absorption. |
| Geriatric use | Use caution; apply sparingly to thin skin, avoid prolonged use due to increased risk of skin atrophy and systemic absorption. |
| 1st trimester | Avoid. Topical corticosteroids may be associated with orofacial clefts when used in first trimester; systemic absorption minimal but caution advised. |
| 2nd trimester | Use only if clearly needed. Controlled studies in pregnant women show no fetal risk but limited data. |
| 3rd trimester | Use only if clearly needed. Prolonged use may cause fetal growth restriction or adrenal suppression. |
Clinical note
Comprehensive clinical and safety monograph for BETADERM (BETADERM).
| Placental transfer | Limited data; corticosteroids cross placenta but extent depends on potency, formulation, and application site. Betamethasone is partially metabolized by placental 11β-HSD2, reducing fetal exposure. |
| Breastfeeding | Use with caution. Topical application to breasts should be avoided. Systemic absorption minimal, but large areas or occlusive dressings may increase exposure. Monitor infant for adrenal suppression. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to betamethasone or any componentUntreated bacterial, fungal, or viral skin infectionsCutaneous tuberculosisRosaceaPerioral dermatitisVaccination reactions
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria, Local irritation, skin atrophy, striae, telangiectasias, and secondary infection may occur, Prolonged use, use on large areas, occlusive dressings, or in pediatric patients increase risk of systemic effects, May mask signs of infection; avoid use in untreated bacterial, fungal, or viral infections, Not for ophthalmic, oral, or intravaginal use, Allergic contact dermatitis may occur with corticosteroids |
| Food/Dietary | No significant food interactions. Avoid excessive alcohol consumption if using on large areas due to possible increased systemic absorption. |
Loading safety data…
| Lactation Rating | L2 (Safer if used cautiously, minimal systemic absorption with small areas/short-term use) |
| Teratogenic Risk | Betamethasone dipropionate (Betaderm) is a topical corticosteroid. Systemic absorption is minimal with short-term use on small areas, but extensive use, occlusion, or application to large areas may increase systemic exposure. In animal studies, corticosteroids cause teratogenicity (cleft palate, intrauterine growth retardation). Human data on topical betamethasone are limited. First trimester: Avoid if possible; use only if potential benefit justifies risk. Second/third trimester: No known structural teratogenicity, but prolonged use may be associated with low birth weight and adrenal suppression in the neonate. Category C. |
| Fetal Monitoring | Monitor for signs of maternal adrenal suppression (e.g., fatigue, hypotension) if used extensively. Neonatal monitoring: assess for adrenal suppression (e.g., hypoglycemia, poor feeding) if mother used high-potency topical corticosteroids for prolonged periods. Fetal growth should be monitored with ultrasound if prolonged use in pregnancy. No specific fetal monitoring required for short-term use. |
| Fertility Effects | Betamethasone, like other corticosteroids, may impair fertility in animal studies, but no specific human data for topical betamethasone. Systemic corticosteroids can affect ovulation and menstrual cycles. Short-term topical use is unlikely to impact fertility. No evidence of permanent fertility impairment. |
| Clinical Pearls | Betamethasone valerate is a potent topical corticosteroid (class III). Use for short courses (max 2 weeks) on thin skin areas. Avoid occlusive dressings over large areas; increase risk of systemic absorption. Do not apply to broken skin, face, groin, or axillae due to atrophy risk. Monitor for HPA axis suppression in children and extensive use. |
| Patient Advice | Apply a thin layer to affected area only, usually twice daily. · Do not use on face, groin, or under diapers/pads unless directed. · Avoid contact with eyes and mucous membranes. · Do not bandage or wrap treated area unless instructed. · Do not stop abruptly after prolonged use; may need to taper. · Tell your doctor if condition worsens or does not improve after 2 weeks. · Report signs of skin thinning, bruising, or infection. |